Christine Murray
General Counsel chez CYTOKINETICS, INCORPORATED
Fortune : 1 837 $ au 31/03/2024
Profil
Christine Murray is currently the Senior Vice President-Regulatory & Quality at Cytokinetics, Inc. She previously worked as an Independent Director at Eiger BioPharmaceuticals, Inc. from 2019 to 2024.
Prior to that, she held the position of Vice President-Regulatory Affairs at Achaogen, Inc. from 2011 to 2015.
She also served as the Vice President-Global Regulatory Affairs at Horizon Pharmaceutical LLC from 2015 to 2017 and at Raptor Pharmaceuticals, Inc. from 2015 to 2017.
From 2018 to 2021, she was the Senior Vice President-Global Regulatory Affairs at Ultragenyx Pharmaceutical, Inc. Ms. Murray completed her undergraduate studies at The University of Liverpool and her graduate studies at Newcastle University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 20/11/2023 | 367 ( 0,02% ) | 1 837 $ | 31/03/2024 |
Postes actifs de Christine Murray
| Sociétés | Poste | Début |
|---|---|---|
| CYTOKINETICS, INCORPORATED | General Counsel | 01/04/2023 |
Anciens postes connus de Christine Murray
| Sociétés | Poste | Fin |
|---|---|---|
| EIGER BIOPHARMACEUTICALS, INC. | Director/Board Member | 15/03/2024 |
| ULTRAGENYX PHARMACEUTICAL INC. | General Counsel | 01/09/2021 |
Raptor Pharmaceuticals, Inc.
 Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Raptor Pharmaceuticals, Inc. operates as a biopharmaceutical company which develops and markets life-altering therapeutics. The company is headquartered in Novato, CA. | Corporate Officer/Principal | 01/02/2017 |
| RAPTOR PHARMACEUTICAL CORP | General Counsel | 01/01/2017 |
| ACHAOGEN | General Counsel | 02/01/2015 |
Formation de Christine Murray
| The University of Liverpool | Undergraduate Degree |
| Newcastle University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| CYTOKINETICS, INCORPORATED | Health Technology |
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| EIGER BIOPHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |
Raptor Pharmaceuticals, Inc.
Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Raptor Pharmaceuticals, Inc. operates as a biopharmaceutical company which develops and markets life-altering therapeutics. The company is headquartered in Novato, CA. | Health Technology |
